WEBULL
News
PCVX
58.51
+2.08%
1.19
Weekly Report: what happened at PCVX last week (0216-0220)?
Weekly Report · 2h ago
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors
TipRanks · 2d ago
A Look At Vaxcyte (PCVX) Valuation After OPUS-3 Phase 3 Dosing Milestone
Simply Wall St · 4d ago
XBI, ROIV, HALO, PCVX: Large Inflows Detected at ETF
NASDAQ · 5d ago
Weekly Report: what happened at PCVX last week (0209-0213)?
Weekly Report · 02/16 09:19
OPUS-3 Launch and Broad VAX-31 Program Could Be A Game Changer For Vaxcyte (PCVX)
Simply Wall St · 02/15 17:15
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vaxcyte (PCVX), Avita Medical (RCEL) and Medtronic (MDT)
TipRanks · 02/13 12:10
Vaxcyte doses first participants in OPUS-3 trial
TipRanks · 02/11 21:30
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31; Company Expects To Report Topline Data From OPUS-3 Trial And OPUS-2 Phase 3 Trial Evaluating Concomitant Administration Of VAX-31 And A Seasonal Influenza Vaccine In First Half Of 2027
Benzinga · 02/11 21:28
Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Previously Vaccinated Adults
Reuters · 02/11 21:05
VAXCYTE INC - TOPLINE DATA FROM OPUS-3 AND OPUS-2 TRIALS EXPECTED IN H1 2027
Reuters · 02/11 21:05
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Barchart · 02/11 15:05
Vaxcyte Inc. to report financial results and provide business update
Reuters · 02/10 21:05
Weekly Report: what happened at PCVX last week (0202-0206)?
Weekly Report · 02/09 09:19
How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline
Simply Wall St · 02/08 05:03
XBI, PCVX, MIRM, RVMD: Large Outflows Detected at ETF
NASDAQ · 02/06 15:50
Vaxcyte to Present at Guggenheim Emerging Outlook Biotech Summit
Reuters · 02/05 21:06
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position
TipRanks · 02/02 21:43
Vaxcyte nimmt durch Aktienemission 600 Millionen Dollar ein
Reuters · 02/02 21:02
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Barchart · 02/02 15:05
More
Webull provides a variety of real-time PCVX stock news. You can receive the latest news about Vaxcyte, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PCVX
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.